Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Express Scripts
Fuji
UBS
Boehringer Ingelheim
Cipla
Citi
Julphar
Accenture

Generated: December 12, 2017

DrugPatentWatch Database Preview

Naproxen - Generic Drug Details

« Back to Dashboard

What are the generic sources for naproxen and what is the scope of naproxen patent protection?

Naproxen
is the generic ingredient in eleven branded drugs marketed by Atnahs Pharma Us, West-ward Pharms Int, Actavis Elizabeth, Invagen Pharms, Mylan Pharms Inc, Pliva, Sandoz, Teva, Amneal Pharms Ny, Aurobindo Pharma Ltd, Chartwell Molecules, Dava Pharms Inc, Glenmark Generics, Hamilton Pharms, Hikma Intl Pharms, Ivax Sub Teva Pharms, Marksans Pharma, Mylan, Perrigo R And D, Purepac Pharm, Roxane, Teva Pharms, Watson Labs, Watson Labs Teva, Zydus Pharms Usa, Bionpharma Inc, Alvogen Malta, Actavis Labs Fl Inc, Bayer, Able, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hikma, Lnk Intl Inc, Perrigo, Sun Pharm Inds Ltd, and Pernix Ireland Ltd, and is included in seventy-two NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are forty-two drug master file entries for naproxen. Seventy suppliers are listed for this compound. There is one tentative approval for this compound.

Pharmacology for naproxen

Medical Subject Heading (MeSH) Categories for naproxen

Tentative approvals for NAPROXEN

Applicant Application No. Strength Dosage Form
u► Subscribe250MGTABLET;ORAL
u► Subscribe500MGTABLET;ORAL
u► Subscribe375MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds LtdNAPROXEN SODIUMnaproxen sodiumTABLET;ORAL091183-001May 20, 2011OTCNoNo► Subscribe► Subscribe► Subscribe► Subscribe
MylanNAPROXENnaproxenTABLET;ORAL074121-002Dec 21, 1993ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Actavis Labs Fl IncNAPROXEN SODIUMnaproxen sodiumTABLET, EXTENDED RELEASE;ORAL075416-003Aug 11, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Watson LabsNAPROXEN SODIUMnaproxen sodiumTABLET;ORAL074195-002Dec 21, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
SandozNAPROXEN SODIUMnaproxen sodiumTABLET;ORAL074162-002Dec 21, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Actavis ElizabethNAPROXENnaproxenTABLET, DELAYED RELEASE;ORAL074936-002Feb 24, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdNAPROXEN SODIUMnaproxen sodiumTABLET;ORAL200629-002Oct 31, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Lnk Intl IncNAPROXEN SODIUMnaproxen sodiumTABLET;ORAL204872-001Jan 23, 2017OTCNoNo► Subscribe► Subscribe► Subscribe► Subscribe
TevaNAPROXEN SODIUMnaproxen sodiumTABLET;ORAL074198-002Dec 21, 1993ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdNAPROXENnaproxenTABLET;ORAL200429-001Nov 8, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: naproxen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-004Apr 15, 1982► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenSUSPENSION;ORAL018965-001Mar 23, 1987► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-004Apr 15, 1982► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenSUSPENSION;ORAL018965-001Mar 23, 1987► Subscribe► Subscribe
Atnahs Pharma UsNAPROSYNnaproxenTABLET;ORAL017581-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
Cantor Fitzgerald
Daiichi Sankyo
Novartis
Merck
Express Scripts
Deloitte
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot